Company: Bristol Myers Squibb
Posted by OpdualagRep_BMS · March 22, 2026
Tags: pipeline, territory
BMS nivolumab/ipilimumab combo is holding its own in NSCLC despite Keytruda's dominance.
The tumor mutational burden story is still working in the right accounts.
My best oncologists appreciate having a mechanistically differentiated option for high TMB patients who aren't responding to anti-PD-1 monotherapy.
Pull-through isn't easy — REMS requirements, monitoring, the immune-related AE counseling burden — but the oncologists who've had good outcomes with the combo are very loyal.
If you're a new BMS rep going into this territory, know the TMB data cold.
That's where the conversation lives.
44 upvotes · 0 comments